entertainment -WSS

entertainment

author：leisure time 2025-09-04 05:52:33 - browse：68

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

focus

WSS

SEC charges former device maker CEO with $41 million fraud

Can sheer will power keep patients alive in their dying hours?

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

UnitedHealth quietly bought dozens of outpatient centers

The problem with charging patients to message their doctors

Bristol Myers buys into radiopharmaceuticals with RayzeBio

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

How to save PrEP access — and even expand it

CDC marks new Covid

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: The latest on Moderna, Apellis, and Merck

entertainment

SEC charges former device maker CEO with $41 million fraud

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Amylyx ALS drug failure raises questions and concerns

With psoriasis trial ahead, Alumis raises $259 million

Former medical device CEO who sold dummy, plastic parts convicted of fraud

focus

focus

explore

focus